juglanin profile

juglanin: antioxidant from Polygonum aviculare; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Polygonum	genus	A plant genus of the family POLYGONACEAE that is an ingredient of Shou-Wu-Pian, a Chinese herbal preparation (DRUGS, CHINESE HERBAL). The common name of black bindweed also refers to TAMUS or Fallopia (use POLYGONACEAE).[MeSH]	Polygonaceae	The only family of the buckwheat order (Polygonales) of dicotyledonous flowering plants. It has 40 genera of herbs, shrubs, and trees.[MeSH]

ID Source	ID
PubMed CID	5318717
CHEMBL ID	469440
CHEBI ID	167534
SCHEMBL ID	16618210
MeSH ID	M000596994

Synonym
5041-67-8
juglanin
CHEBI:167534
kaempferol 3-arabinofuranoside
3-[(2s,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
CHEMBL469440
LMPK12111839
HY-N3442
CS-7981
SCHEMBL16618210
Q15720546
3-(((2s,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)oxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-chromen-4-one
MS-27302
XJ161837
3-(alpha-l-arabinofuranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-one
kaempferol 3-o-alpha-l-arabinofuranoside

Research Excerpts

Overview

Juglanin (JUG) is a flavonoid with excellent antioxidant, anti-inflammatory, neuroprotective and anticancer properties. It has been reported that juglanin has a potent inhibitory effect on inflammation and certain type of cancers.

Excerpt	Reference	Relevance
"Juglanin (JUG) is a flavonoid with excellent antioxidant, anti-inflammatory, neuroprotective and anticancer properties."	( Protective effect of Juglanin against doxorubicin-induced cognitive impairment in rats: Effect on oxidative, inflammatory and apoptotic machineries. Ashaolu, TJ; Olatunji, OJ; Tang, J; Wang, L; Wei, T, 2022)	1.76
"Juglanin is a natural compound belonging to flavonoids, and it has been reported that juglanin has a potent inhibitory effect on inflammation and certain type of cancers."	( The Inhibitory Effects of Juglanin on Adipogenesis in 3T3-L1 Adipocytes. Jin, X; Wang, G; Wang, H; Wang, K; Wu, B; Xu, W, 2020)	1.58
"Juglanin (Jug) is a natural compound extracted from the crude Polygonumaviculare, showing anti-inflammatory and anti-diabetic effects."	( Juglanin protects against high fat diet-induced renal injury by suppressing inflammation and dyslipidemia via regulating NF-κB/HDAC3 signaling. Dai, X; Ge, C; Hu, LF; Kuang, Q; Li, Q; Lou, DS; Sun, Y; Tan, J; Xu, M; Yi, C; Zhong, S, 2021)	2.79
"Juglanin is a natural production, mainly extracted from green walnut husks of Juglans mandshurica, exhibiting various bioactivities."	( A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. Jie, J; Liu, H; Peng, LP; Wen, ZM; Zhang, Y, 2017)	1.5
"Juglanin is a natural compound extracted from the crude Polygonum aviculare, exhibiting anti-inflammatory, anti-oxidant and anti-cancer activities."	( Juglanin ameliorates LPS-induced neuroinflammation in animal models of Parkinson's disease and cell culture via inactivating TLR4/NF-κB pathway. Xu, RS; Zhang, FX, 2018)	2.64
"Juglanin is a natural product mainly isolated from green walnut husks of Juglans mandshurica, which isconsidered as the functional composition among a series of compounds."	( Juglanin suppresses fibrosis and inflammation response caused by LPS in acute lung injury. Dong, ZW; Yuan, YF, 2018)	2.64
"Juglanin is a natural product, which is predominantly extracted from Polygonum aviculare, and is considered a functional component among its various compounds."	( Juglanin ameliorates UVB‑induced skin carcinogenesis via anti‑inflammatory and proapoptotic effects in vivo and in vitro. Hou, GR; Lan, HM; Wang, Q; Zeng, K, 2018)	2.64

Effects

Juglanin has been reported to have anti-inflammation activity. It has potential implication as a candidate for vascular intervention of atherosclerosis.

Excerpt	Reference	Relevance
"Juglanin has been reported to have anti-inflammation activity."	( Juglanin inhibits IL-1β-induced inflammation in human chondrocytes. Chen, X; Huo, S; Wang, X; Zhang, C, 2019)	2.68
"Juglanin has potential implication as a candidate for vascular intervention of atherosclerosis."	( Juglanin suppresses oscillatory shear stress-induced endothelial dysfunction: An implication in atherosclerosis. Ding, Z; Quan, X; Xie, Z; Zhang, L; Zhao, J, 2020)	2.72
"Juglanin has demonstrated a range of anti-inflammatory effects in various tissues and cell types."	( Amelioration of Juglanin against LPS-Induced Activation of NLRP3 Inflammasome in Chondrocytes Mediated by SIRT1. Li, Y; Sun, T; Wang, J; Wang, T, 2021)	1.69
"Juglanin has been reported to exert marked protective effects in various diseases via the inhibition of inﬂammation and tumor cell growth."	( Juglanin ameliorates UVB‑induced skin carcinogenesis via anti‑inflammatory and proapoptotic effects in vivo and in vitro. Hou, GR; Lan, HM; Wang, Q; Zeng, K, 2018)	2.64

Actions

Excerpt	Reference	Relevance
"And juglanin was found to suppress fructose-feeding-induced activation of these signaling pathways compared with the model group administrated only with fructose."	( The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. Fang, PP; Jin, LX; Lin, W; Lin, XZ; Pan, CW; Yi, YX; Zheng, Y; Zhou, GY, 2016)	1.22

Treatment

Excerpt	Reference	Relevance
"Treatment of juglanin might be an effective therapeutic strategy for preventing hepatitis."	( The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. Fang, PP; Jin, LX; Lin, W; Lin, XZ; Pan, CW; Yi, YX; Zheng, Y; Zhou, GY, 2016)	1.09

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Class	Description
flavonoids	Any organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
glycoside	A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID551199	Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by FMCA method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New Hedgehog/GLI signaling inhibitors from Excoecaria agallocha.
AID338974	Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID551198	Cytotoxicity against human DU145 cells after 24 hrs by FMCA method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New Hedgehog/GLI signaling inhibitors from Excoecaria agallocha.
AID551196	Inhibition of human HH/Gli1-mediated transcriptional activity in tetracycline-treated human HaCaT cells treated after 12 hrs of tetracycline addition by luciferase reporter gene assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New Hedgehog/GLI signaling inhibitors from Excoecaria agallocha.
AID551197	Cytotoxicity against human PANC1 cells after 24 hrs by FMCA method	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	New Hedgehog/GLI signaling inhibitors from Excoecaria agallocha.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	9 (52.94)	24.3611
2020's	8 (47.06)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
glycosides [no description available]	4.34	16
D-fructopyranose [no description available]	2.13	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.21	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
quercitrin [no description available]	2.06	1	alpha-L-rhamnoside; monosaccharide derivative; quercetin O-glycoside; tetrahydroxyflavone	antileishmanial agent; antioxidant; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; plant metabolite
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	2.06	1	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
kaempferol 3-o-rhamnoside kaempferol 3-O-rhamnoside: from apple (Malus domestica) leaves; structure in first source. afzelin : A glycosyloxyflavone that is kaempferol attached to an alpha-L-rhamnosyl residue at position 3 via a glycosidic linkage.	2.06	1	glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone	anti-inflammatory agent; antibacterial agent; plant metabolite
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.25	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.06	1
Cancer of Pancreas [description not available]	2.06	1
Cancer of Prostate [description not available]	2.06	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.06	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.06	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.06	1
Cognitive Decline [description not available]	2.41	1
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.41	1
Innate Inflammatory Response [description not available]	3.58	7
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.58	7
Alveolitis, Fibrosing [description not available]	2.61	2
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	2.61	2
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.25	1
Cerebral Ischemia [description not available]	7.25	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.25	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.25	1
Atherogenesis [description not available]	2.25	1
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	7.25	1
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	2.31	1
Dyslipidemia [description not available]	7.31	1
Insulin Sensitivity [description not available]	2.31	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.31	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.31	1
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	2.31	1
Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.	2.31	1
Cancer of Lung [description not available]	2.15	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.15	1
Autosomal Dominant Juvenile Parkinson Disease [description not available]	2.17	1
Age-Related Memory Disorders [description not available]	2.17	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.17	1
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	2.17	1
Lung Injury, Acute [description not available]	2.17	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	7.17	1
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	7.17	1
B16 Melanoma [description not available]	2.17	1
Cancer of Skin [description not available]	2.17	1
Skin Neoplasms Tumors or cancer of the SKIN.	2.17	1
Hepatitis INFLAMMATION of the LIVER.	7.13	1
Breast Cancer [description not available]	7.15	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.15	1

juglanin

Description

Cross-References

Synonyms (16)

Research Excerpts

Overview

Effects

Actions

Treatment

Drug Classes (2)

Bioassays (5)

Research

Studies (17)

Market Indicators

Research Demand Index: 24.97

Study Types

juglanin

Description

Related Flora

Cross-References

Synonyms (16)

Research Excerpts

Overview

Effects

Actions

Treatment

Drug Classes (2)

Bioassays (5)

Research

Studies (17)

Market Indicators

Research Demand Index: 24.97

Study Types

Related Drugs (7)

Related Conditions (40)